Warner Chilcott (WCRX +5.9%) says the FDA has approved its treatment for postmenopausal...

|By:, SA News Editor

Warner Chilcott (WCRX +5.9%) says the FDA has approved its treatment for postmenopausal osteoporosis, with a U.S. commercial launch scheduled for early next year. The delayed-release tablet, Atelvia, is part of the Actonel family of osteoporosis treatments Warner Chilcott acquired from Procter & Gamble (PG) last year. (PR)